| Paris Brain Institute (ICM) | |
|---|---|
| Logo placeholder | |
| Location | Paris, France (Pitié-Salpêtrière Hospital) |
| Type | Translational Research Center |
| Established | 2010 |
| Website | https://icm-institute.org |
| Focus Areas | [Alzheimer's Disease](/diseases/alzheimers), [Parkinson's Disease](/diseases/parkinsons-disease), [ALS](/diseases/als), [Huntington's Disease](/diseases/huntingtons) |
| Research Groups | 50+ research teams |
The Paris Brain Institute (Institut du Cerveau et de la Moelle épinière, ICM) is a world-leading translational research center dedicated to neurological and psychiatric diseases. Located at the Pitié-Salpêtrière Hospital in Paris, one of Europe's largest teaching hospitals, the institute brings together clinicians, researchers, and patients in a unique collaborative environment dedicated to understanding and treating diseases of the brain and spinal cord[1].
Founded in 2010 as a major initiative in French neuroscience research, the ICM represents one of the most ambitious neuroscience projects in Europe. The institute was established with support from the French government, the Assistance Publique-Hôpitaux de Paris (AP-HP), and leading research organizations[2]. Its mission is to accelerate the translation of basic neuroscience discoveries into clinical applications for patients with neurodegenerative and neurological disorders.
The Paris Brain Institute emerged from a strategic recognition that major advances in neuroscience required unprecedented collaboration between basic researchers and clinicians. The institute was established in 2010 on the historic site of Pitié-Salpêtrière Hospital, which has been a center of neurological excellence since the 19th century when Jean-Martin Charcot pioneered the study of neurological diseases.
Since its founding, the ICM has grown from an initial cohort of 20 research teams to over 50 teams, with more than 600 researchers and clinicians working across the full spectrum of neuroscience research. The institute has invested heavily in state-of-the-art infrastructure, including advanced neuroimaging facilities, genomics platforms, and clinical research units.
The institute's primary mission is to understand the nervous system and develop new treatments for brain and spinal cord diseases through:
The ICM hosts one of Europe's largest programs in neurodegenerative disease research, with particular focus on:
Research on Alzheimer's Disease encompasses:
The institute has established the French Alzheimer's Disease Biomarker Network, coordinating biomarker research across 15 university hospitals in France.
The ICM is a global leader in Parkinson's Disease research:
The ICM hosts a comprehensive ALS research program:
Research on Huntington's Disease includes:
The ICM maintains state-of-the-art research facilities:
The ICM maintains active partnerships with:
Pasquier F et al. Alzheimer disease biomarkers in French cohorts (2023). 2023. ↩︎
Duron E et al. Early-onset Alzheimer disease in France (2021). 2021. ↩︎
Hannequin D et al. APP and PSEN1 mutations in French AD families (2020). 2020. ↩︎
Le Bers D et al. Tau PET in French AD cohorts (2023). 2023. ↩︎
Corvol JC et al. LRRK2 and Parkinson disease in French cohorts (2018). 2018. ↩︎
Lesage S et al. French PD genetics consortium findings (2016). 2016. ↩︎
Delamarre A et al. Alpha-synuclein seeds in Parkinson disease (2021). 2021. ↩︎
Vidailhet M et al. Deep brain stimulation for Parkinson disease (2018). 2018. ↩︎ ↩︎
Duret M et al. Movement disorders and deep brain stimulation in France (2019). 2019. ↩︎
Simonnet S et al. Neuroinflammation in Parkinson disease (2022). 2022. ↩︎
Bertran F et al. Biomarkers in French Parkinson cohorts (2021). 2021. ↩︎
Rouvière L et al. French ALS genetics registry (2022). 2022. ↩︎
Blasco H et al. C9orf72 expansions in French ALS (2021). 2021. ↩︎
Gougeon L et al. SOD1 mutations in French ALS families (2020). 2020. ↩︎
Monet M et al. HTT lowering therapies in development (2021). 2021. ↩︎
Brice A et al. Genetics of Parkinson disease (2019). 2019. ↩︎